(Q34919089)

5 August 2017

1 reference

title

Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited (English)

1 reference

5 August 2017

0 references

3

Gregory Y H Lip

1 reference

5 August 2017

2

Eduard Shantsila

1 reference

5 August 2017

Timothy Watson

1

1 reference

PubMed ID

19135613

5 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

5 August 2017

1 reference

5 August 2017

373

1 reference

5 August 2017

155-166

1 reference

5 August 2017

9658

1 reference

Does atrial fibrillation confer a hypercoagulable state?

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Virchow's triad revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

von Willebrand factor, fibrinogen, and soluble P-selectin levels after mitral valve replacement versus mitral valve repair

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Histological substrate of atrial biopsies in patients with lone atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial stunning: determinants and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

The L-type Ca2+-channel subunits α1C and β2 are not downregulated in atrial myocardium of patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

The optimal management of cardioversion of atrial fibrillation or flutter: still a 'stunning' problem

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

The myocardial matrix and the development and progression of ventricular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

The fibrosis and atrial fibrillation: is the transforming growth factor-beta 1 a candidate etiology of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Electrical Remodeling of the Atria in Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial fibrillation and atrial enlargement in patients with mitral stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Left atrial size and the risk of ischemic stroke in an ethnically mixed population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Predictors of systemic embolism in patients with mitral stenosis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation--a transesophageal echocardiographic study in 500 patients with cereb

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Spontaneous echo contrast in the left atrium during paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Pulsed Doppler characterization of left atrial appendage flow.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Echocardiographic "smoke" is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Hypofibrinolysis in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Increased intracardiovascular clotting in patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Hypercoagulopathy in stroke patients with nonvalvular atrial fibrillation: hematologic and cardiologic investigations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

The prothrombotic risk of diabetes mellitus in atrial fibrillation and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Left atrial appendage dysfunction in chronic nonvalvular atrial fibrillation is significantly associated with an elevated level of brain natriuretic peptide and a prothrombotic state

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Relation of left atrial spontaneous echo contrast with prethrombotic state in atrial fibrillation associated with systemic hypertension, idiopathic dilated cardiomyopathy, or no identifiable cause (lone).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Left Atrial Appendage Function and Abnormal Hypercoagulability in Patients With Atrial Flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Thrombogenesis in mitral regurgitation and aortic stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

D-dimer level influences thromboembolic events in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Radioimmunoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrinopeptide A generation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Activation and destruction of platelets in patients with rheumatic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Plasma adenosine levels and platelet activation in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Platelet adhesion in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Transvenous cryoablation reduces platelet activation during pulmonary vein ablation compared with radiofrequency energy in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Coagulation indicators in patients with paroxysmal atrial fibrillation: effects of electric and pharmacologic cardioversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Clotting state after cardioversion of atrial fibrillation: a haemostasis index could detect the relationship with the arrhythmia duration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Prolonged activation of hemostatic markers following conversion of atrial flutter to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Is atrial fibrillation an inflammatory disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Atrial fibrillation and C-reactive protein: searching for local inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Inflammation in the genesis and perpetuation of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Inflammatory markers according to types of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Cytokine-induced alteration of platelet and hemostatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

C-reactive protein and atrial fibrillation: "evidence for the presence of inflammation in the perpetuation of the arrhythmia"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Cancer and the prothrombotic state

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Matrix metalloproteinases and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Shear stress regulates endothelial nitric oxide synthase expression through c-Src by divergent signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Nitric oxide released from activated platelets inhibits platelet recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Dual regulatory effects of nitric oxide on plasminogen activator inhibitor type 1 expression in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Downregulation of Endocardial Nitric Oxide Synthase Expression and Nitric Oxide Production in Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Inflammation and angiotensin II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Identification, diagnosis and assessment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

D-dimers in atrial fibrillation: a further step in risk stratification of thrombo-embolism?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960040-4

7 January 2021

10.1016/S0140-6736(09)60040-4

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

19135613